Elite Pharmaceuticals, Inc.ELTP

Key ratios

Operating cash flow growth

-0.2%TTM

2026 218.5%

EPS growth

537.5%2024

FCF / Sales

15.3%2026

2025 6.9%2024 -7.1%

Net margin

40.2%TTM

2026 30.1%2025 -5.1%2024 35.5%

ROA

17.8%TTM

2026 26.6%2025 14.7%2024 10.8%

ROE

74.3%TTM

2026 58.9%2025 -7.8%2024 46.5%

Revenue growth

33.7%TTM

2026 77.1%2025 48.4%2024 65.8%

Recent news

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information 2026-08-13 · Newsfile

Track ELTP in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer